# Polaryx Therapeutics, Inc. (PLYX)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/polaryx-therapeutics-inc/ JSON: https://steadybase.io/company/polaryx-therapeutics-inc.json Checked Nov 21, 2026. Latest filing read: Nov 12, 2026.

## Company

- Legal name: Polaryx Therapeutics, Inc.
- Ticker: PLYX (Nasdaq)
- SEC CIK: 0002075320
- Industry: Pharmaceutical Preparations (SIC 2834)
- Headquarters: Paramus, NJ
- Fiscal year ends: December 31
- SEC filer category: <br>Emerging growth company
- Website: polaryx.com
- Investor relations: https://investors.polaryx.com
- LinkedIn: https://www.linkedin.com/company/polaryxtherapeutics
- Next earnings date: Feb 11, 2027

## Key facts

- Operating income: -$7.8M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 24, 2026). Source: https://www.sec.gov/Archives/edgar/data/2075320/000121390026033064/0001213900-26-033064-index.html
- Net income: -$9.0M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 24, 2026). Source: https://www.sec.gov/Archives/edgar/data/2075320/000121390026033064/0001213900-26-033064-index.html
- SG&A: $1.6M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 24, 2026). Source: https://www.sec.gov/Archives/edgar/data/2075320/000121390026033064/0001213900-26-033064-index.html
- Employees: 11 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/2075320/000121390026033064/ea0281719-10k_polaryx.htm
- Shares outstanding: 49,845,993 as of Oct 31, 2026 (10-Q filed Nov 12, 2026). Source: https://www.sec.gov/Archives/edgar/data/2075320/000121390026118950/0001213900-26-118950-index.html
- Auditor: Grant Thornton LLP, Edison, New Jersey, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/2075320/000121390026033064/ea0281719-10k_polaryx.htm

## Business

PLX-200 (gemfibrozil), our most advanced drug candidate, is an oral small molecule for the treatment of LSDs. PLX-200 is a repurposed, reformulated drug that we are pursuing through a 505(b)(2) regulatory pathway and is designed to be administered through a novel and proprietary oral solution. We are advancing PLX-200 through a Phase 2 proof-of-concept basket trial, which we refer to as SOTERIA (PLX-200-600), and expect to initiate this trial in the second half of 2026.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/2075320/000121390026033064/ea0281719-10k_polaryx.htm

## Officers and directors

- Alex Keun Mo Yang, Chief Executive Officer. Source: Form 4 filed May 28, 2026, https://www.sec.gov/Archives/edgar/data/2075320/000121390026062322/0001213900-26-062322-index.htm
- G. Michael Landis, Chief Financial Officer. Source: Form 4 filed Feb 20, 2026, https://www.sec.gov/Archives/edgar/data/2075320/000121390026018845/0001213900-26-018845-index.htm
- Lisa L. Bollinger, M.D., Chief Medical Officer. Source: 10-K filed Mar 24, 2026, https://www.sec.gov/Archives/edgar/data/2075320/000121390026033064/ea0281719-10k_polaryx.htm
- Andrew John O., Chief Investment Officer. Source: Form 3 filed Jan 29, 2026, https://www.sec.gov/Archives/edgar/data/2075320/000121390026009564/0001213900-26-009564-index.htm
- Lisa Bollinger, Chief Medical Officer. Source: Form 3 filed Jan 29, 2026, https://www.sec.gov/Archives/edgar/data/2075320/000121390026009567/0001213900-26-009567-index.htm
- Francis A. Braun III, Director. Source: 10-K filed Mar 24, 2026, https://www.sec.gov/Archives/edgar/data/2075320/000121390026033064/ea0281719-10k_polaryx.htm
- Mitchel Berger, M.D., Director. Source: 10-K filed Mar 24, 2026, https://www.sec.gov/Archives/edgar/data/2075320/000121390026033064/ea0281719-10k_polaryx.htm

## Recent 8-K events

- Sep 14, 2026: Item 5.07, Submission of matters to a vote of security holders. Source: https://www.sec.gov/Archives/edgar/data/2075320/000121390026099416/ea0305352-8k_polaryx.htm
- Sep 1, 2026: Item 7.01, Regulation FD disclosure; Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2075320/000121390026096235/ea0303928-8k_polaryx.htm
- Jul 21, 2026: Item 5.02, Departure or appointment of directors or officers; compensation. Source: https://www.sec.gov/Archives/edgar/data/2075320/000121390026080041/ea0298434-8k_polaryx.htm
- Jul 17, 2026: Item 5.08, Item 5.08; Item 8.01, Other events. Source: https://www.sec.gov/Archives/edgar/data/2075320/000121390026078912/ea0298274-8k_polaryx.htm
- May 28, 2026: Item 1.01, Entry into a material definitive agreement; Item 3.02, Unregistered sales of equity securities; Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2075320/000121390026062155/ea0291692-8k_polaryx.htm

## Insider trades (Form 4)

- May 27, 2026: Alex Keun Mo Yang (Chief Executive Officer) bought 88,453 shares, about $360,004. Source: https://www.sec.gov/Archives/edgar/data/2075320/000121390026062322/0001213900-26-062322-index.htm
- May 27, 2026: Partners Healthcare Ltd Mstone (Director) bought 88,453 shares, about $360,004. Source: https://www.sec.gov/Archives/edgar/data/2075320/000121390026062322/0001213900-26-062322-index.htm
- Feb 18, 2026: G. Michael Landis (Chief Financial Officer) bought 2,867 shares, about $7,999. Source: https://www.sec.gov/Archives/edgar/data/2075320/000121390026018845/0001213900-26-018845-index.htm

## Latest filings

- 8-K filed Sep 14, 2026: https://www.sec.gov/Archives/edgar/data/2075320/000121390026099416/ea0305352-8k_polaryx.htm
- 10-K filed Mar 24, 2026: https://www.sec.gov/Archives/edgar/data/2075320/000121390026033064/ea0281719-10k_polaryx.htm
- 10-Q filed Aug 13, 2026: https://www.sec.gov/Archives/edgar/data/2075320/000121390026089118/ea0301429-10q_polaryx.htm
- DEF 14A filed Jul 28, 2026: https://www.sec.gov/Archives/edgar/data/2075320/000121390026082339/ea0298291-01.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/

